Search

Displaying results 5101 - 5110 of 10000 in total
  1. Drug

    Chromous sulfate

    go.drugbank.com/drugs/DB14530
    Approved

  2. Drug

    DOTMP HO-166

    go.drugbank.com/drugs/DB05380
    Experimental

    It is an experimental therapy that is being developed by NeoRx Corporation. … SRT is designed to be used in combination with high-dose chemotherapy producing a direct therapeutic effect on the tumor sites in the bone plus a general bone-marrow effect to destroy myeloma cells in

  3. Drug

    Darifenacin

    go.drugbank.com/drugs/DB00496
    ApprovedInvestigational

    This block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.

    Categories: Genito Urinary System and Sex Hormones, Drugs for Urinary Frequency and IncontinenceProducts: EMSELEX 15MG RET, EMSELEX 15MG RETARDTABL
  4. Drug

    Pradefovir mesylate

    go.drugbank.com/drugs/DB05478
    Investigational

    Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver. … The novel prodrug is highly stable in both plasma and tissues and demonstrated potent preclinical and clinical anti-HBV activity.

  5. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor. … It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase

  6. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. … It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [A14009].

    Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor Blockers
  7. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

    Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATE
  8. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  9. Drug

    Iberdomide

    go.drugbank.com/drugs/DB12101
    Investigational

    [L64055,L64057] It is given in combination with daratumumab and hyaluronidase-fihj and dexamethasone. … at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

  10. Drug

    Affitope AD01

    go.drugbank.com/drugs/DB06086
    Investigational

    Affitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease. … AD01 is a short peptide (7 amino acids in length) that induces Aß-targeting antibodies, therefore lowering Aß aggregates.